Literature DB >> 34292983

Clinical outcomes of adults hospitalized for laboratory confirmed respiratory syncytial virus or influenza virus infection.

Magdalena Chorazka1, Domenica Flury2, Kathrin Herzog3, Werner C Albrich2, Danielle Vuichard-Gysin1,4.   

Abstract

OBJECTIVES: Respiratory syncytial virus (RSV) can cause severe disease in adults, but far less is known than for influenza. The aim of our study was to compare the disease course of RSV infections with influenza infections among hospitalized adults.
METHODS: We retrieved clinical data from an ongoing surveillance of adults hospitalized with RSV or influenza virus infection in two acute care hospitals in North-Eastern Switzerland during the winter seasons 2017/2018 and 2018/2019. Our main analysis compared the odds between RSV and influenza patients for admission to an intensive care unit (ICU) or in-hospital death within 7 days after admission.
RESULTS: There were 548 patients, of whom 79 (14.4%) had an RSV and 469 (85.6%) an influenza virus infection. Both groups were similar with respect to age, sex, smoking status, nutritional state, and comorbidities. More RSV patients had an infiltrate on chest radiograph on admission (46.4% vs 29.9%, p = .007). The proportion of patients with RSV who died or were admitted to ICU within seven days after admission was 19.0% compared to 10.2% in influenza patients (p = .024). In multivariable analysis, a higher leukocyte count (adjusted OR 1.07, 95% CI 1.02-1.13, p = .013) and the presence of a pneumonic infiltrate (aOR 3.41, 95% CI 1.93-6.02) significantly increased the risk for experiencing the adverse primary outcome while the effect of the underlying viral pathogen became attenuated (aOR 1.18, 95% CI 0.58-2.41, p = .0.655).
CONCLUSIONS: Our results suggest that RSV is responsible for clinical courses at least as severe as influenza in adults. This supports the need for better guidance on diagnostic strategies as well as on preventive and therapeutic measures for hospitalized adults with RSV infection.

Entities:  

Year:  2021        PMID: 34292983     DOI: 10.1371/journal.pone.0253161

Source DB:  PubMed          Journal:  PLoS One        ISSN: 1932-6203            Impact factor:   3.240


  25 in total

1.  Accurate PCR Detection of Influenza A/B and Respiratory Syncytial Viruses by Use of Cepheid Xpert Flu+RSV Xpress Assay in Point-of-Care Settings: Comparison to Prodesse ProFlu.

Authors:  Daniel M Cohen; Jennifer Kline; Larissa S May; Glenn Eric Harnett; Jane Gibson; Stephen Y Liang; Zubaid Rafique; Carina A Rodriguez; Kevin M McGann; Charlotte A Gaydos; Donna Mayne; David Phillips; Jason Cohen
Journal:  J Clin Microbiol       Date:  2018-01-24       Impact factor: 5.948

2.  Comparison of the Cepheid Xpert Xpress Flu/RSV assay and commercial real-time PCR for the detection of influenza A and influenza B in a prospective cohort from China.

Authors:  Xiaohui Zou; Kang Chang; Yeming Wang; Mengxue Li; Wang Zhang; Chunlei Wang; Binghuai Lu; Zhujia Xiong; Jiajing Han; Yulin Zhang; Jiankang Zhao; Bin Cao
Journal:  Int J Infect Dis       Date:  2019-01-08       Impact factor: 3.623

Review 3.  Respiratory syncytial virus infection in adults.

Authors:  A R Falsey; E E Walsh
Journal:  Clin Microbiol Rev       Date:  2000-07       Impact factor: 26.132

4.  Is clinical recognition of respiratory syncytial virus infection in hospitalized elderly and high-risk adults possible?

Authors:  Edward E Walsh; Derick R Peterson; Ann R Falsey
Journal:  J Infect Dis       Date:  2007-02-15       Impact factor: 5.226

Review 5.  Risk of nosocomial respiratory syncytial virus infection and effectiveness of control measures to prevent transmission events: a systematic review.

Authors:  Clare E French; Bruce C McKenzie; Caroline Coope; Subhadra Rajanaidu; Karthik Paranthaman; Richard Pebody; Jonathan S Nguyen-Van-Tam; Julian P T Higgins; Charles R Beck
Journal:  Influenza Other Respir Viruses       Date:  2016-03-24       Impact factor: 4.380

6.  Estimates of hospitalization attributable to influenza and RSV in the US during 1997-2009, by age and risk status.

Authors:  Gonçalo Matias; Robert Taylor; François Haguinet; Cynthia Schuck-Paim; Roger Lustig; Vivek Shinde
Journal:  BMC Public Health       Date:  2017-03-21       Impact factor: 3.295

7.  Clinical characteristics and outcome of respiratory syncytial virus infection among adults hospitalized with influenza-like illness in France.

Authors:  P Loubet; N Lenzi; M Valette; V Foulongne; A Krivine; N Houhou; G Lagathu; S Rogez; S Alain; X Duval; F Galtier; D Postil; P Tattevin; P Vanhems; F Carrat; B Lina; O Launay
Journal:  Clin Microbiol Infect       Date:  2016-11-27       Impact factor: 8.067

8.  Clinical Features, Severity, and Incidence of RSV Illness During 12 Consecutive Seasons in a Community Cohort of Adults ≥60 Years Old.

Authors:  Edward A Belongia; Jennifer P King; Burney A Kieke; Joanna Pluta; Ali Al-Hilli; Jennifer K Meece; Vivek Shinde
Journal:  Open Forum Infect Dis       Date:  2018-11-27       Impact factor: 3.835

9.  Severe Morbidity and Mortality Associated With Respiratory Syncytial Virus Versus Influenza Infection in Hospitalized Older Adults.

Authors:  Bradley Ackerson; Hung Fu Tseng; Lina S Sy; Zendi Solano; Jeff Slezak; Yi Luo; Christine A Fischetti; Vivek Shinde
Journal:  Clin Infect Dis       Date:  2019-07-02       Impact factor: 9.079

10.  Influenza- and respiratory syncytial virus-associated morbidity and mortality in the nursing home population.

Authors:  Shelley E Ellis; Christopher S Coffey; Edward F Mitchel; Robert S Dittus; Marie R Griffin
Journal:  J Am Geriatr Soc       Date:  2003-06       Impact factor: 5.562

View more
  1 in total

1.  Clinical Outcome of Viral Respiratory Tract Infections in Hospitalized Adults in Norway: High Degree of Inflammation and Need of Emergency Care for Cases With Respiratory Syncytial Virus.

Authors:  Sara Debes; Jon Birger Haug; Birgitte Freiesleben de Blasio; Jonas Christoffer Lindstrøm; Christine Monceyron Jonassen; Susanne Gjeruldsen Dudman
Journal:  Front Med (Lausanne)       Date:  2022-04-29
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.